Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update
05 Agosto 2019 - 8:00AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”),
a specialty biopharmaceutical company primarily focused on
developing and commercializing products in the therapeutic areas of
allergy, respiratory disease and opioid overdose, announced today
that it will host an investor conference call on Thursday, August
8, 2019 at 2:00 pm Pacific Time to discuss its financial and
operating results for the second quarter of 2019 as well as provide
an update on business developments and activities. The
company’s press release concerning its second quarter 2019
financial results will be available after 1:00 p.m. Pacific Time on
August 8, 2019, on its website
at www.adamispharmaceuticals.com, and the company also expects
to file its quarterly report on Form 10-Q for the second quarter
ended June 30, 2019, on that date.
Event: Adamis Pharmaceuticals Second Quarter
2019 Conference Call
Date: Thursday, August 8, 2019
Time: 2:00 pm PT (5:00 pm ET)
U.S. Dial-in (Toll Free): 1-866-288-0540
TOLL/International Dial-in: 1-323-994-2131
Conference ID: 4399286
Dr. Dennis J. Carlo, President and CEO of Adamis, will host the
call along with other members of the management team. The
call is open to the public and will provide an update on recent
developments, events that have taken place during this quarter and
certain target milestones and goals for future periods.
Forward-looking statements concerning expectations regarding future
company performance may be made during the conference call.
A live audio webcast of the conference call will also be
available via this link –
http://public.viavid.com/index.php?id=135744. Participants
should access this webcast site 10 minutes before the start of the
call. In addition, a telephone playback of the call will be
available after approximately 5:00 pm PT on August 8, 2019.
To listen to the replay, call toll free 1-844-512-2921 within the
United States or 1-412-317-6671 when calling internationally
(toll). Please use the replay PIN number 4399286.
About Adamis
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
respiratory disease, allergy and opioid overdose. The
company’s SYMJEPI™ (epinephrine) Injection 0.3mg and
SYMJEPI™ (epinephrine) Injection 0.15mg products were approved
by the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. In July, Sandoz, a division
of Novartis Group, announced it had fully launched both SYMJEPI
products in the U.S. Adamis is developing additional
products, including a naloxone injection product candidate, ZIMHI™,
for the treatment of opioid overdose, and a metered dose inhaler
and dry powder inhaler product candidates for the treatment of
asthma and COPD. The company’s subsidiary, U.S. Compounding,
Inc., compounds sterile prescription drugs, and certain nonsterile
drugs for use by hospitals, clinics and surgery centers throughout
most of the United States.
Contacts: Mark Flather Senior Director,
Investor Relations& Corporate Communications Adamis
Pharmaceuticals Corporation (858)
412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024